Spark layoffs won't derail Philadelphia's biotech surge, city official says
Philly's life sciences sector is strategizing to remain at the forefront, despite recent shakeups at cell and gene therapy pioneer Spark Therapeutics.
Turmoil at one big company doesn't necessarily indicate the end of a sector's strength, according to Rebecca Grant, senior director of life sciences and innovation for the city's Department of Commerce. While acknowledging the negative impact of job losses caused by the layoffs at Spark, Grant said she's still optimistic about the industry at large.
'People in these situations, they know how to pivot the innovation that they've created thus far,' Grant told reporter Sarah Huffman on Technical.ly Speaking, our monthly segment on WURD Radio's 'Reality Check' hosted by Tonya Pendleton. '[They] will help gene therapy and life sciences to move forward.'
Earlier this year, Spark's parent company Roche announced a restructuring of the organization and 300 layoffs at its Philadelphia office. The abrupt shift — following Spark's major success story, from Penn spinout to the era's largest VC-backed exit — caused a moment of reflection for the cell and gene therapy scene.
From Grant's perspective, it's been a time to recognize the moral issues at stake and the ecosystem's role in supporting these expensive endeavors.
'As these therapies come about that can actually cure people, and they don't have to continue to take drugs down the line, I think it takes all of us to get involved,' Grant said.
Hopefully, jobs come with that. As a global company, Grant said Roche has the opportunity to bring more production jobs to Philadelphia.
Those types of roles aren't just for scientists with advanced degrees. There are also training programs for 'aseptic techniques,' or keeping an area sterile, and biomanufacturing in the lab at local organizations like the Wistar Institute and the Skills Initiative.
'The research that's continuing,' Grant said, 'is how to make these treatments less expensive and how to manufacture them so that they are more affordable.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Technical.ly
08-06-2025
- Technical.ly
Most companies don't IPO, so here's how to plan for your likely exit
The most important day of an entrepreneur's journey might be the one when it ends. The big question: Will it end on your terms? That's the dilemma behind most startup exits, whether they take place through a merger, acquisition or an initial public offering (IPO). Experts put that distinction front and center during the 2025 Builders Conference session titled 'M&A or IPO: What is Your Company's Destination?' Moderated by Mike Ravenscroft of the University System of Maryland's Maryland Momentum Fund, the conversation featured attorney Kim Klayman of Ballard Spahr and Alexis Grant, founder of the M&A-focused newsletter They Got Acquired. Together, they laid out a candid, often under-explored roadmap of what founders really need to know about exiting — and why waiting until it's too late to plan is a mistake. 'Think about it early,' Grant said. 'Gives you more options.' The numbers are clear, Ravenscroft noted: Only a tiny fraction of companies ever go public, and even among VC-backed firms, IPOs are rare. The vast majority of exits happen via mergers and acquisitions (M&A). The panelists agreed that the perception gap around what makes an exit 'successful' can obscure the reality of its true impact. A $7 million sale might be life-changing for a bootstrapped founder with majority ownership. But if that same company had raised venture capital at a high valuation, the founder might walk away with little or nothing. 'If someone raises $5 million and they sell for $5 million, they probably didn't get any money,' Grant said. That disconnect is even more stark during economic downturns or slower capital markets. Klayman pointed to the increase in smaller companies acquiring other small firms — sometimes simply to pad revenue, not gain technology. But these all-stock or acqui-hire (in which a company gets acquired for their talent) deals can mask another story: Sometimes, the best-case scenario is simply survival. 'The reality is most companies end up in an M&A situation, even if it's a multi-generational business,' Klayman said. 'It does end up a lot of times in an M&A transaction if there is no succession plan.' The hardest parts that too few talk about Asked what founders need to prepare for, both panelists were unequivocal: The due diligence process is brutal. 'For many [founders], due diligence ends up being a second job,' Grant said, adding: 'You also have to keep running the business, and you want to run it in a way that performance does not drop, because that's the worst thing that can happen when you're going through a deal.' That's why both she and Klayman emphasized the need to 'get your house in order' — and do so early. From knowing who owns the IP to having clean cap tables and documented promises of equity shares, small oversights can kill a deal late in the game. 'I have actually seen one deal die because the whole company was built on this one piece of software, and that's what the buyer wanted,' Klayman said. 'And it was like, a software developer did it 25 years earlier, and they didn't paper it because it wasn't that important. And the deal just died.' She advised founders to use tools like Carta or diligence-prep software to identify red flags before a transaction is even on the table. Attorneys can help, but so can platforms that flag missing consents or unsigned option grants. 'Being organized is like 95% of the battle,' Klayman said. The stories behind the headlines Of course, learning these details can be difficult when many companies don't discuss them soon after an M&A takes place. The panel also pulled back the curtain on how mergers and acquisitions are framed in public — and how different the internal reality can be. Grant, whose company profiles founder-led exits, said PR statements often overhype vague synergies and downplay job losses or underwhelming returns. She added that sellers are often far more candid a year or two post-sale. 'Most of the stories we write, they're usually at least six months after the acquisition has taken place,' Grant said. 'The seller is more open to sharing real details at that point.' Klayman agreed: Sometimes the announcements make it seem like someone got a bunch of money, when usually the investors, even if they're paid first, 'are getting like 10 cents on the dollar,' she said. 'I don't think that people want those types of transactions to happen,' she said, 'but when they do happen, it takes effort and, I think, actually responsible founders to make it happen.' All emphasized that outcomes must be evaluated in context. Founders may sell to give their team stability, find a new role or offload a company responsibly instead of shutting down. What matters, they said, is alignment between a founder's goals and their investors' expectations. The closing message to founders was clear: Plan for your endgame from the beginning. Think through potential paths — and not just the flashy ones. Ask investors what their expectations are. Build a network that includes not just mentors and peers, but service providers who understand exits and won't charge you just to ask questions. 'If you don't know what success looks like, you're going to be poor no matter what,' Ravenscroft said, 'because you won't know it if you get it.'
Technical.ly
09-05-2025
- Technical.ly
Spark layoffs won't derail Philadelphia's biotech surge, city official says
Philly's life sciences sector is strategizing to remain at the forefront, despite recent shakeups at cell and gene therapy pioneer Spark Therapeutics. Turmoil at one big company doesn't necessarily indicate the end of a sector's strength, according to Rebecca Grant, senior director of life sciences and innovation for the city's Department of Commerce. While acknowledging the negative impact of job losses caused by the layoffs at Spark, Grant said she's still optimistic about the industry at large. 'People in these situations, they know how to pivot the innovation that they've created thus far,' Grant told reporter Sarah Huffman on Speaking, our monthly segment on WURD Radio's 'Reality Check' hosted by Tonya Pendleton. '[They] will help gene therapy and life sciences to move forward.' Earlier this year, Spark's parent company Roche announced a restructuring of the organization and 300 layoffs at its Philadelphia office. The abrupt shift — following Spark's major success story, from Penn spinout to the era's largest VC-backed exit — caused a moment of reflection for the cell and gene therapy scene. From Grant's perspective, it's been a time to recognize the moral issues at stake and the ecosystem's role in supporting these expensive endeavors. 'As these therapies come about that can actually cure people, and they don't have to continue to take drugs down the line, I think it takes all of us to get involved,' Grant said. Hopefully, jobs come with that. As a global company, Grant said Roche has the opportunity to bring more production jobs to Philadelphia. Those types of roles aren't just for scientists with advanced degrees. There are also training programs for 'aseptic techniques,' or keeping an area sterile, and biomanufacturing in the lab at local organizations like the Wistar Institute and the Skills Initiative. 'The research that's continuing,' Grant said, 'is how to make these treatments less expensive and how to manufacture them so that they are more affordable.'
Technical.ly
04-04-2025
- Technical.ly
Spark Therapeutics files notice to lay off 300 employees this year
Cell and gene therapy standout Spark Therapeutics is undergoing its second shakeup in a month, with plans to lay off about half of its workforce. Several hundred people will be affected. A WARN notice, which companies file to provide advance notice of layoffs, reported 298 eliminated positions in the Philadelphia region. A Spark Therapeutics spokesperson told the Philadelphia Business Journal on Thursday it would be laying off 337 of its almost 650 employees. These changes are expected to occur in three waves: in May, July and at the end of 2025. The remaining 310 employees will be incorporated into parent company Roche, a multinational pharmaceutical company. Spark first announced on January 30 the decision to integrate more of its work into Roche, spokesperson Denise Bradley told The impacted employees will be eligible for severance, outplacement services and will be able to apply for other roles within Roche. Spark's plans for its University City-based Gene Therapy Innovation Center in Philadelphia have not changed, Bradley said. Last month, Roche classified the former startup as a financial loss following the end of its trial for a hemophilia A gene therapy treatment, the Philadelphia Inquirer reported. The company is still working on a new Hemophilia A gene product, Spark previously told The layoff announcement comes less than a year after Spark's previous workforce reduction, when it let less than 50 of its employees go in July 2024. At the end of last year, the company welcomed Roche veteran Sylke Poehling as its new CEO, replacing Ron Phillip, who had been in the role since 2022. Spark's year of downsizing Recent struggles at Spark, which was founded by Jeffrey Marrazzo in 2013 and was considered a big Philadelphia success story, indicate the need for the gene therapy sector to make manufacturing more cost effective, Rebecca Grant, senior director of life sciences and innovation for the city's Department of Commerce, previously told But the company itself heavily contributed to the development of the industry as a whole. 'They really created a lot of recognition for gene therapy and innovation,' Grant said. 'Now more people understand what gene therapy means and how it can literally cure disease.' In 2021, the company announced plans for a 500,000-square-foot Gene Therapy Innovation Center in University City. At the time, Spark said the new site would house over 500 jobs. The Innovation Center is still expected to be completed next year, Spark spokesperson Bradley previously told The Penn spinout is known for developing the first FDA-approved gene therapy, Luxturna. Pharma giant Roche acquired Spark in 2019 for $4.8 billion, the largest VC-backed exit in Philadelphia at the time. 'Gene therapy is not a huge sector, and Spark was a trailblazer,' Dean Miller, president of the Philadelphia Alliance for Capital and Technologies, previously said. '[It's] never easy when your trailblazer starts to disappear a little further.' Sarah Huffman is a 2022-2024 corps member for Report for America, an initiative of The Groundtruth Project that pairs young journalists with local newsrooms. This position is supported by the Lenfest Institute for Journalism.
